FDA’s compounded GLP-1 crackdown: What changed after Ozempic, Wegovy, Mounjaro, and Zepbound shortages ended

The main GLP-1 story in 2026 is no longer the shortage itself. It is what changed after the shortages ended.

Once semaglutide and tirzepatide came off the FDA shortage list, many compounded copycat products lost the broad shortage-based rationale that had helped keep them available during the supply crunch. Since February 2026, the FDA has shifted from temporary flexibility to active enforcement against companies mass-marketing compounded GLP-1s as substitutes for Ozempic, Wegovy, Mounjaro, and Zepbound.

That matters to patients because compounded GLP-1 products are not FDA-approved. They are also not the same as generic drugs. Some may still be legally compounded in limited, patient-specific situations, but the rules are narrower than they were when the branded products were in shortage.

What changed, in plain language

The legal landscape changed when the shortages officially ended.

Tirzepatide, the active ingredient in Mounjaro and Zepbound, was declared no longer in shortage in late 2024. Semaglutide, the active ingredient in Ozempic and Wegovy, followed in early 2025. The FDA then allowed temporary transition periods so patients would not be abruptly cut off while supply normalized. Those grace periods ended in 2025.

By 2026, the agency had moved into a different phase. On February 6, 2026, the FDA announced that it intended to step up action against non-FDA-approved compounded GLP-1 drugs that were being mass-marketed as similar alternatives to approved products. On March 3, 2026, the agency said it had sent warning letters to 30 telehealth companies over false or misleading marketing of compounded GLP-1 products. On April 1, 2026, the FDA published a reminder that compounders still must meet the conditions in federal law for exemptions under sections 503A and 503B.

The practical takeaway is simple: shortages used to be a broad justification for many copycat compounded GLP-1 products. Now that semaglutide and tirzepatide are off the shortage list, that broad justification is gone.

When compounded GLP-1s may still be allowed

This does not mean every compounded GLP-1 product is illegal or banned.

Compounding can still be lawful in some limited circumstances. Under section 503A, a state-licensed pharmacy or physician generally compounds a medication for an individual patient after receiving a prescription. But there is a major limit: they generally cannot regularly make products that are essentially copies of commercially available drugs unless a prescriber documents a meaningful difference for a specific patient.

Under section 503B, outsourcing facilities can compound drugs in larger batches, but they have separate restrictions. One of the key ones is that semaglutide and tirzepatide are not on the 503B bulks list, and they are no longer on the FDA drug shortage list. That sharply limits the shortage-based pathway that some outsourcing facilities had relied on.

In other words, individualized compounding may still exist for a real patient need. Mass-marketed copycat products promoted as easy substitutes for approved GLP-1 drugs are the bigger enforcement target now.

Why the crackdown matters to everyday patients

For many people, compounded GLP-1s were about access and cost. During the shortages, some patients turned to compounded products because they could not find the branded drug, could not get insurance coverage, or could not afford the cash price.

Those access problems have not magically disappeared. Even when a shortage is resolved nationally, people may still run into local stock gaps, insurance denials, step therapy rules, or high out-of-pocket costs. The FDA has also noted that intermittent local supply disruptions can still happen as products move through the supply chain.

But the end of the shortages does mean something important: difficulty getting a brand-name drug does not automatically make a copycat compounded version equivalent, appropriate, or lawful.

The safety problems the FDA is flagging

The FDA says its concerns are not just legal or technical. They are also about patient safety.

Among the problems the agency has highlighted:

Dosing errors. The FDA says it has received multiple reports of dosing mistakes involving compounded injectable semaglutide, including some cases that required hospitalization. Problems included patients measuring the wrong dose and clinicians miscalculating doses.
Doses beyond approved labeling. The agency says it has received reports involving compounded semaglutide or tirzepatide used in doses or titration schedules beyond the approved labeling.
Warm shipments and poor refrigeration. Injectable GLP-1 products need proper temperature control. The FDA says some compounded products arrived warm or with inadequate ice packs, which can raise quality concerns.
Fraudulent labels. The agency says some products carried false labeling, including names of pharmacies that did not exist or names of licensed pharmacies that, according to the FDA, did not actually make the product.
Counterfeit and illegally marketed products. Some online products may contain the wrong ingredients, too much or too little active ingredient, or no active ingredient at all.
Semaglutide salt forms. The FDA has warned against semaglutide sodium and semaglutide acetate, which are different active ingredients from the semaglutide used in approved drugs.

It is also important to keep the evidence in perspective. Adverse event reports can be useful warning signals, but they do not prove that a compounded product caused a given injury. Reporting is also incomplete because some pharmacies are not required to submit adverse event reports to the FDA, so the real number of problems may be higher or lower than the reports suggest.

What the evidence says about altered compounded formulas

A recent journal-indexed article adds to the concern that compounded GLP-1 products may differ more than many patients realize.

This was not a randomized trial and it did not test patient outcomes. Instead, it was a journal-indexed editorial analysis that reviewed 33 compounded semaglutide and tirzepatide products advertised online. The authors found that many products differed from approved formulations by route, strength, or added ingredients. Nearly half included extra ingredients such as vitamin B12, glycine, niacinamide, docusate, or ondansetron. Many single-ingredient products were sold as sublingual or orally disintegrating forms instead of the familiar approved injections or tablets.

The study has important limits. It looked at websites, not lab-tested products, and it cannot tell us whether any specific altered formulation is safe, unsafe, better, or worse in real patients. Still, it supports a key point for consumers: some compounded semaglutide and tirzepatide products are not simple one-to-one stand-ins for the approved drugs.

What patients should ask before continuing a compounded GLP-1

If you are currently using a compounded GLP-1 product, do not stop abruptly on your own. Talk with your prescriber or pharmacist first, especially if you are using it for diabetes, obesity treatment, or another ongoing medical reason.

Here is a practical checklist to bring to that conversation:

Why is compounding needed for me specifically? Ask whether there is a patient-specific reason, not just a general convenience or marketing claim.
Who made this product? Ask for the name of the pharmacy or outsourcing facility that actually compounded it.
Is the pharmacy state-licensed? If you received the medicine through a telehealth company, ask which licensed pharmacy filled it.
What exactly is in it? Ask for the active ingredient, strength, dosage form, and any added ingredients such as vitamin B12 or other compounds.
Is it semaglutide base or a salt form? Ask directly whether the product contains semaglutide sodium or semaglutide acetate.
How was it shipped and stored? If it is injectable, ask what temperature controls were used and what to do if the package arrived warm.
Does the label make sense? Check for spelling errors, bad addresses, missing lot information, unclear beyond-use dates, or other signs the label may not be legitimate.
Should I switch to an FDA-approved product now? Ask your prescriber whether the approved drug is now available, what it would cost, and how to switch safely if needed.

What this means for readers

The shortage era gave many patients the impression that compounded GLP-1s were a routine substitute for Ozempic, Wegovy, Mounjaro, or Zepbound. The FDA is now making clear that this is not how the agency sees the post-shortage market.

The big change is not that compounding vanished. It is that the broad shortage-based opening has closed. In 2026, the pressure is on companies that mass-market non-FDA-approved compounded semaglutide and tirzepatide as if they were the same as approved drugs.

For patients, the safest next step is not panic and not abrupt discontinuation. It is verification. Confirm who prescribed the product, who compounded it, what ingredients it contains, how it was stored, and whether an FDA-approved option is now the better fit for your treatment plan.

Sources

This article is for general informational purposes only and is not medical advice. Research findings can be early, limited, or subject to change as new evidence emerges. For personal guidance, diagnosis, or treatment, consult a licensed clinician. For current outbreak or public health guidance, follow your local health department, the CDC, or another relevant public health authority.